13F Filings History of Hound Partners, LLC

Latest 13F report
Q4 2025 - 17 Feb 2026
Value $
$721,290,523
Signature - Title
Douglas Marks - CFO & CCO
Location
New York, NY
Summary
This page shows a list of all the recent 13F filings made by Hound Partners, LLC. Form 13F is required to be filed within 45 days of the end of a calendar quarter. Hound Partners, LLC reported 36 stock holdings with total value $721,290,523 as of Q4 2025. Top holdings included CCL, PLTR, NVDA, NCLH, and SE.

Notify me when Hound Partners, LLC files a new 13F portfolio report.

⭐ Subscribe ⭐
Holdings Value
Quarter Holdings Value $ Bought Sold Net Top Holdings Form Type Filing Time
Q4 2025 36 $721,290,523 +$208,228,359 -$233,306,426 -$25,078,067 CCL, PLTR, NVDA, NCLH, SE 13F-HR 17 Feb 2026, 17:08
Q3 2025 30 $778,597,703 +$84,535,012 -$123,638,319 -$39,103,307 CCL, GS, SE, NVDA, NCLH 13F-HR 14 Nov 2025, 15:58
Q2 2025 28 $739,894,070 +$230,802,735 -$86,564,398 +$144,238,337 CCL, SE, NVDA, NCLH, EXPE 13F-HR 14 Aug 2025, 16:23
Q1 2025 17 $504,265,932 +$356,080,816 -$44,690,181 +$311,390,635 NVDA, NCLH, CCL, EXPE, BIO 13F-HR 15 May 2025, 15:18
Q4 2024 18 $208,090,279 +$58,549,668 -$254,743,906 -$196,194,238 MSFT, DG, BIO, ENTG, ARW 13F-HR 14 Feb 2025, 16:12
Q3 2024 17 $399,517,346 +$87,800,218 -$259,874,121 -$172,073,903 IBIT, BKNG, FTNT, MSFT, GLNG 13F-HR 14 Nov 2024, 16:32
Q2 2024 16 $498,616,584 +$312,013,200 -$134,541,703 +$177,471,497 FTNT, IBIT, BKNG, BIO, GLNG 13F-HR 14 Aug 2024, 16:19
Q1 2024 15 $335,488,562 +$85,131,499 -$104,133,976 -$19,002,477 BIO, GLNG, HCA, IBIT, MSFT 13F-HR 15 May 2024, 16:18
Q4 2023 12 $320,936,079 +$61,980,656 -$205,783,468 -$143,802,812 BIO, HCA, VPU, GLNG, KEX 13F-HR 14 Feb 2024, 14:23
Q3 2023 18 $451,104,371 +$115,887,626 -$88,811,125 +$27,076,501 QQQ, BIO, VPU, MSFT, HCA 13F-HR 14 Nov 2023, 16:25
Q2 2023 16 $440,668,347 +$118,979,556 -$97,474,445 +$21,505,111 BIO, QQQ, MSFT, FIS, VOO 13F-HR 14 Aug 2023, 15:32
Q1 2023 14 $397,248,687 +$132,338,426 -$108,013,200 +$24,325,226 BIO, MSFT, QQQ, FIS, WDAY 13F-HR 15 May 2023, 15:35
Q4 2022 13 $338,192,419 +$72,899,589 -$302,810,328 -$229,910,739 HCA, QQQ, FRSH, MSFT, BIO 13F-HR 14 Feb 2023, 15:14
Q3 2022 16 $526,733,000 +$17,974,008 -$629,727,815 -$611,753,807 IWM, VOO, HCA, MSFT, ROST 13F-HR 14 Nov 2022, 15:40
Q2 2022 24 $1,232,697,000 +$323,294,736 -$320,376,062 +$2,918,674 VOO, IWM, MSFT, SPY, HCA 13F-HR 15 Aug 2022, 15:50
Q1 2022 27 $1,540,829,000 +$374,296,971 -$384,881,275 -$10,584,304 VOO, IWM, KEX, MSFT, VTWO 13F-HR 13 May 2022, 15:16
Q4 2021 106 $1,700,120,000 +$256,208,266 -$445,209,118 -$189,000,852 VOO, IWM, KEX, MSFT, HCA 13F-HR 14 Feb 2022, 13:49
Q3 2021 206 $1,825,410,000 +$339,606,411 -$406,273,593 -$66,667,182 VOO, MSFT, IWM, KEX, META 13F-HR 15 Nov 2021, 16:10
Q2 2021 250 $2,001,196,000 +$207,075,732 -$335,166,341 -$128,090,609 VOO, KEX, FTCHF, META, BABA 13F-HR 16 Aug 2021, 16:21
Q1 2021 247 $2,036,094,000 +$880,684,745 -$466,027,472 +$414,657,273 VOO, FIS, META, KEX, FTCHF 13F-HR 17 May 2021, 16:22
Q4 2020 124 $1,577,572,000 +$473,271,107 -$633,936,845 -$160,665,738 FTCHF, HCA, KEX, WDAY, META 13F-HR 16 Feb 2021, 16:28
Q3 2020 94 $1,457,977,000 +$541,225,503 -$247,063,628 +$294,161,875 FTCHF, KEX, META, WDAY, AER 13F-HR 16 Nov 2020, 17:04
Q2 2020 49 $1,086,082,000 +$371,939,673 -$611,350,430 -$239,410,757 AER, META, W, MSFT, SATS Restatement 14 Aug 2020, 19:54
Q1 2020 36 $1,061,499,000 +$299,840,153 -$225,329,751 +$74,510,402 CARG, SATS, META, MSFT, NXST 13F-HR 15 May 2020, 16:20
Q4 2019 27 $1,428,442,000 +$221,427,772 -$506,349,984 -$284,922,212 NXST, SATS, ARMK, META, CARG 13F-HR 14 Feb 2020, 16:13
Q3 2019 25 $1,564,895,000 +$278,731,297 -$649,432,567 -$370,701,270 CARG, NXST, META, SPR, MSFT 13F-HR 14 Nov 2019, 16:10
Q2 2019 29 $2,032,383,000 +$292,250,850 -$671,094,684 -$378,843,834 CARG, RPM, SPR, META, MSFT 13F-HR 14 Aug 2019, 16:17
Q1 2019 30 $2,326,665,000 +$238,931,930 -$1,531,109,239 -$1,292,177,309 SPR, CARG, META, RPM, MSFT 13F-HR 15 May 2019, 15:27
Q4 2018 29 $3,112,251,000 +$389,991,022 -$878,793,505 -$488,802,483 FOXA, SPR, META, HLT, RPM 13F-HR 14 Feb 2019, 14:08
Q3 2018 32 $4,301,462,000 +$970,014,013 -$847,820,697 +$122,193,316 FOXA, SPR, HLT, META, PCG 13F-HR 14 Nov 2018, 16:31
Q2 2018 21 $4,179,189,000 +$692,355,221 -$714,321,115 -$21,965,894 FOXA, SPR, META, HLT, CACC 13F-HR 14 Aug 2018, 15:10
Q1 2018 22 $3,971,407,000 +$1,539,033,318 -$1,055,758,094 +$483,275,224 FOXA, LKQ, MHK, CACC, SPR 13F-HR 15 May 2018, 16:21
Q4 2017 21 $3,637,394,000 +$510,774,503 -$1,275,774,308 -$764,999,805 HLT, LKQ, SPR, EXPE, NXST 13F-HR 14 Feb 2018, 18:00
Q3 2017 24 $4,156,264,000 +$1,103,461,201 -$1,177,127,100 -$73,665,899 HLT, SPR, EXPE, LKQ, ANDV 13F-HR 14 Nov 2017, 16:20
Q2 2017 22 $3,959,104,000 +$787,379,778 -$966,207,424 -$178,827,646 HLT, SPR, TSO, LKQ, EXPE 13F-HR 14 Aug 2017, 16:02
Q1 2017 24 $3,871,840,000 +$1,230,120,472 -$1,600,859,374 -$370,738,902 HLT, SPR, TSO, SERV, CACC 13F-HR 15 May 2017, 16:08
Q4 2016 25 $4,081,311,000 +$852,983,152 -$390,028,584 +$462,954,568 A104PS, SPR, TSO, SERV, CHTR 13F-HR 14 Feb 2017, 14:50
Q3 2016 26 $3,396,108,000 +$587,110,422 -$497,674,445 +$89,435,977 SPR, TSO, A104PS, SERV, BIDU 13F-HR 14 Nov 2016, 15:05
Q2 2016 19 $3,175,528,000 +$819,784,599 -$594,243,422 +$225,541,177 SPR, TSO, A104PS, BIDU, SERV 13F-HR 15 Aug 2016, 13:37
Q1 2016 22 $3,096,769,000 +$566,708,102 -$689,761,472 -$123,053,370 SPR, BIDU, FLT, TSO, CRI 13F-HR 16 May 2016, 15:34
Q4 2015 20 $3,712,784,000 +$570,293,635 -$653,782,163 -$83,488,528 SPR, VRX, FLT, CRI, TSO 13F-HR 16 Feb 2016, 14:42
Q3 2015 21 $3,962,141,000 +$969,714,667 -$591,710,970 +$378,003,697 VRX, SPR, TSO, FLT, CRI 13F-HR 16 Nov 2015, 12:49
Q2 2015 20 $4,025,174,000 +$1,276,589,632 -$1,324,658,510 -$48,068,878 VRX, SPR, CRI, TSO, FLT 13F-HR 14 Aug 2015, 15:22
Q1 2015 24 $3,965,894,000 +$1,396,361,369 -$683,586,537 +$712,774,832 VALEANT PHARMACEUTICALS INTL, SPR, CRI, CHTR, FLT 13F-HR 15 May 2015, 12:24
Q4 2014 20 $3,005,943,000 +$553,673,235 -$507,351,863 +$46,321,372 SPR, CRI, VRX, CHTR, FLT 13F-HR 17 Feb 2015, 11:23
Q3 2014 19 $2,741,360,000 +$532,929,370 -$154,556,433 +$378,372,937 VRX, CRI, SPR, CHTR, FLT 13F-HR 14 Nov 2014, 11:20
Q2 2014 18 $2,307,129,000 +$353,041,758 -$175,134,052 +$177,907,706 VRX, CRI, CHTR, SPR, FLT 13F-HR 12 Aug 2014, 15:49
Q1 2014 18 $2,029,557,000 +$636,061,230 -$248,694,367 +$387,366,863 VRX, CRI, CHTR, TSO, FLT 13F-HR 12 May 2014, 15:16
Q4 2013 20 $1,614,802,000 $0 $0 $0 VRX, CRI, FLT, GRA, CHTR 13F-HR 14 Feb 2014, 13:47